RT Journal Article
T1 Colorectal peritoneal metastases: Optimal management review.
A1 Sánchez-Hidalgo, Juan Manuel
A1 Rodríguez-Ortiz, Lidia
A1 Arjona-Sánchez, Álvaro
A1 Rufián-Peña, Sebastián
A1 Casado-Adam, Ángela
A1 Cosano-Álvarez, Antonio
A1 Briceño-Delgado, Javier
K1 Colorectal cancer
K1 Cytoreductive surgery
K1 Hyperthermic intraperitoneal chemotherapy
K1 Peritoneal carcinomatosis
K1 Peritoneal metastases
AB The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies.
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14347
UL http://hdl.handle.net/10668/14347
LA en
DS RISalud
RD Apr 9, 2025